Cutaneous malignant melanoma: ESMO clinical recommendations for diagnosis, treatment and follow-up

Annals of Oncology

Volumn 19, Issue SUPPL. 2, 2008, Pages

  Dummer, R ^a,c   Hauschild, A ^b,c   Jost, L ^b,c  

^a UNIVERSITY OF KIEL   (Germany)

^b Kantonsspital ^*  (Germany)

^c ESMO HEAD OFFICE   (Switzerland)

Author keywords

[No Author keywords available]

Indexed keywords

ALPHA INTERFERON; CANCER VACCINE; DACARBAZINE; INTERLEUKIN 2; MELPHALAN; NITROSOUREA; TEMOZOLOMIDE; TUMOR NECROSIS FACTOR; VINCA ALKALOID; VISCUM ALBUM LECTIN;

ADJUVANT THERAPY; ARTICLE; CANCER IMMUNIZATION; CANCER INCIDENCE; CANCER LOCALIZATION; CANCER MORTALITY; CANCER PALLIATIVE THERAPY; CANCER RADIOTHERAPY; CANCER STAGING; CENTRAL NERVOUS SYSTEM METASTASIS; CLINICAL TRIAL; COMPUTER ASSISTED TOMOGRAPHY; DRUG EFFICACY; DRUG MEGADOSE; FOLLOW UP; HUMAN; INOPERABLE CANCER; LYMPH NODE BIOPSY; LYMPH NODE METASTASIS; LYMPHADENECTOMY; MELANOMA; MONOTHERAPY; OVERALL SURVIVAL; PATIENT COUNSELING; PATIENT INFORMATION; POSITRON EMISSION TOMOGRAPHY; POSTOPERATIVE CARE; PRIORITY JOURNAL; PSYCHOSOCIAL CARE; VISCERAL METASTASIS; INCIDENCE; METASTASIS; PATHOLOGY; PRACTICE GUIDELINE; SKIN TUMOR;

FOLLOW-UP STUDIES; HUMANS; INCIDENCE; MELANOMA; NEOPLASM METASTASIS; NEOPLASM STAGING; SKIN NEOPLASMS;

EID: 45149130392     PISSN: 09237534     EISSN: 15698041     Source Type: Journal    
DOI: 10.1093/annonc/mdn100     Document Type: Article

References (14)

1. de Vries E, Bray FI, Coebergh JW, Parkin DM. Changing epidemiology of malignant cutaneous melanoma in Europe 1953-1997: Rising trends in incidence and mortality but recent stabilizations in western Europe and decreases in Scandinavia. Int J Cancer 2003; 107: 119-126.
2. Bono A, Tolomio E, Trincone S et al. Micro-melanoma detection: A clinical study on 206 consecutive cases of pigmented skin lesions with a diameter < or = 3 mm. Br J Dermatol 2006; 155: 570-573.
3. Thompson JF, Scolyer RA, Kefford RF. Cutaneous melanoma. Lancet 2005; 365: 687-701.
4. Eggermont AM. Critical appraisal of IFN-alpha-based adjuvant therapy in stage II-III malignant melanoma. Expert Rev Anticancer Ther 2002; 2: 563-569.
5. Lens MB, Dawes M. Interferon alfa therapy for malignant melanoma: A systematic review of randomized controlled trials. J Clin Oncol 2002; 20: 1818-1825.
6. Kleeberg UR, Suciu S, Broecker EB et al. Final results of the EORTC 18871/DKG 80-1 randomised phase III trial: RIFN-alpha 2b versus rIFN-gamma versus ISCADOR M versus observation after surgery in melanoma patients with either high risk primary (thickness > 3 mm) or regional lymph node metastasis. Eur J Cancer 2004; 40: 390-402.
7. Farshad A, Burg G, Panizzon R, Dummer R. A retrospective study of 150 patients with lentigo maligna and lentigo maligna melanoma and the efficacy of radiotherapy using Grenz or soft X-rays. Br J Dermatol 2002; 146: 1042-1046.
8. Australian Cancer Network. Guidelines for the management of cutaneous melanoma. Sydney: Stone Press 1997.
9. Dummer R, Panizzon R, Bloch PH, Burg G. Updated Swiss guidelines for the treatment and follow-up of cutaneous melanoma. Dermatology 2005; 210: 39-44.
10. Huncharek M, Caubet JF, McGarry R. Single-agent DTIC versus combination chemotherapy with or without immunotherapy in metastatic melanoma: A meta-analysis of 3273 patients from 20 randomized trials. Melanoma Res 2001; 11: 75-81.
11. Kaufmann R, Spieth K, Leiter U et al. Temozolomide in combination with interferon-alfa versus temozolomide alone in patients with advanced metastatic melanoma: A randomized, phase III, multicenter study from the Dermatologic Cooperative Oncology Group. J Clin Oncol 2005; 23: 9001-9007.
12. Titus-Ernstoff L, Perry AE, Spencer SK et al. Multiple primary melanoma: two-year results from a population-based study. Arch Dermatol 2006; 142: 433-438.
13. Beyeler M, Waldispuhl S, Strobel K et al. Detection of melanoma relapse: first comparative analysis on imaging techniques versus S100 protein. Dermatology 2006; 213: 187-191.
14. Kleeberg UR, Garbe C. Recommendations for follow-up of patients with cutaneous melanoma. Dermatol Ther 1999; 10: 83-87.